Eva Lin

PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with <i>PIK3CA</i> -Mutated Solid Tumors and in Preclinical Models

NRF2 supports non-small cell lung cancer growth independently of CBP/p300-enhanced glutathione synthesis

RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy

An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance

Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study

Data from ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy

Data from ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy

Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers

Distinct resistance mechanisms arise to allosteric vs. ATP-competitive AKT inhibitors

ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma

Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma

Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation

Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors

ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy

USP7 small-molecule inhibitors interfere with ubiquitin binding

Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors